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A B S T R A C T
It is generally thought that fragile X-associated tremor/ataxia syndrome (FXTAS) represents a late-onset neurode-
generative disorder occuring in male carriers of a premutation expansion (55–200 CGG repeats) in the fragile X mental
retardation 1 (FMR 1) gene. However, several female patients with FXTAS have also been reported recently. Here, we de-
scribe a 23-year old woman with positive family history of mental retardation and autism who presented clinically with
action tremor, ataxia, emotional disturbances and cognitive dysfunction. Magnetic resonance imaging (MRI) of the brain
showed diffuse cortical atrophy, while 1H-MR spectroscopy (MRS) revealed decreased levels of N-acetylaspartate (NAA)
in the cerebellum, basal ganglia, and pons. Genetic testing confirmed heterozygous FMR 1 gene premutation of 100 CGG
repeats in the abnormal allele and 29 CGG repeats in the normal allele. We concluded that FXTAS may be an under-rec-
ognized disorder, particularly in women.
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Introduction
Fragile X tremor/ataxia syndrome (FXTAS) is a pro-
gressive neurological condition that has been recognized
in a subgroup of adult older than 50 years of age carriers
of the FMR1 (fragile site mental retardation 1 gene)
premutation (55–200 repeats)1,2. Until recently, premu-
tations had only been associated with premature ovarian
failure in 21% of carriers3. The main clinical feature of
this new syndrome is a progressive cerebellar ataxia that
may be accompanied by intention tremor. These signs
were chosen as clinical inclusion criteria by Jacquemont
et al.2. Other clinical features include short-term mem-
ory loss, executive function deficits, gradual cognitive de-
cline leading to dementia5–7, parkinsonim and autonomic
dysfunction1,2,4, peripheral neuropathy, loss of vibration
and tactile sensation and reflexes in the distal lower
extremities2, and emotional problems and psychiatric
symptoms including anxiety, mood lability, and depre-
ssion2,8–12. Traditionally thought to affect men older than
50 years in known fragile X families, FXTAS syndrome
affect women as well, with only a few case studies re-
ported11–15. The second X chromosome in women may be
protective against FXTAS13,14. Premutation carriers ha-
ve slightly reduced levels of the FMR1 protein product
(FMRP), but dramatically (two- to eightfold) elevated
levels of FMR1 messenger RNA (mRNA)16. Results of
previous studies on the prevalence of FMR1 premutation
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alleles within populations with movement disorders have
not been consistent3. Siginificant proportions of premu-
tation carriers were found in three cohorts of male patients
with spinocerebellar ataxia (2.2%, 4.1%, and 5%17–19), in
contrast to patients with essential tremor20, atypical
parkinsonism21, and multiple system atrophy (MSA)3,22
with which FXTAS is very unlikely to be confused. Brun-
berg et al.23 and Jacquemont et al.12 reported associated
neuroimaging findings which include global brain atro-
phy and white matter disease, with a characteristic en-
hancement of T2 signal intensity in the middle cerebellar
peduncles (MCP). Further studies of the clinical, neuro-
imaging and genetic effects of the premutation allele in
the both female and male carriers are therefore needed.
Case Report
Patient is a 23-years old female who experienced on-
set of social phobia at age 20 years when she lost her job.
Autism was followed a months later by difficulties in per-
forming fine motor skills, progressive left hand numb-
ness and tremor, ataxia, reduced psychomotor activity
and disinhibition. In the family history, her brother suf-
fered from similar symptoms in childhood, and died at 22
years of age without specific diagnosis.
Severe tremors and ataxia developed in her 23 result-
ing in frequent falling. Levodopa was prescribed for her
tremor and bradikinesia and was found to be of minor
helpful. On examination, she had left hand tremor at
rest, normal eye movement, dysarthria, nonfluent speech,
amimia, bradyphrenia, dysarthria, retarded motor activ-
ity, freezing episodes, and difficulties initiating move-
ments. Tandem walking demonstrated ataxia, and gait
was mildly broad based. Postural stability was markedly
impaired. Tone was increased, while power and reflexes
were normal. She did not complain of urinary inconti-
nence and had no clinical evidence of autonomic failure.
These symptoms responded partially to low-dose levo-
dopa treatment. Neuropsychological assesment showed
moderate generalized cognitive decline from the patient
premorbid level. The first electroencephalogram (EEG)
examination revealed dysrhytmic pattern with parox-
ysms of slow variant spike and wave complexes. Electro-
myogram and nerve conduction studies showed no eviden-
ce of diffuse polyneuropathy. Cognitive evoked poten-
tials, P300 visual potential was normal in the counting
processing, and abnormal in the motoric reactions. P300
auditory potential showed significant disturbances in
conscious processing. Spectral positron emission com-
puted tomography (SPECT) revealed normal cerebral
and cerebellar perfusions. Routine blood processing sho-
wed significant hypercholesterolemia (7.8 mol/L) and
LDL(6.0 mmol/L). Urin analysis revealed nonspecific uri-
ne neutral amino acids, including histidine, serine, tauri-
ne, glutamine, alanine, glutaminic acid, b-aminobutyric
acid, phenylalanine, valine, and leucine. Cerebrospinal
fluid (CSF) findings were within normal range.
Structural and functional imaging results were not
fully consistent with the diagnosis of FXTAS in the pres-
ent case. Initial MRI scans of the brain at 1.5 T (Sie-
mens) showed premature, global brain atrophy (Figure
1), high intensity signal in the pons (Figure 2), and deep
cerebellar white matter hyperintensity signal (Figure 3).
There were neither thining of the oblique transverse di-
ameters of either MCPs (Figure 4) nor white matter
changes in the cerebrum. 1H-MR spectroscopic studies
were performed with a point-resolved spectroscopic se-
quence on a 2.0 T MR imager (GE Medical Systems) at
the Croatian Institute for Brain Research, University of
Zagreb. Spectra were obtained and analyzed by one ob-
server (G.P.). We used metabolite ratios found in the
literature24 for comparison to our results. Peak area ra-
tios of NAA/Cr, NAA/Cho, Cho/Cr, Glx/Cr and mL/Cr in
the occipital white matter, globus pallidus, pons, and cer-
ebellar white matter were calculated. The first spectrum
was obtained from the globus pallidus and showed peak
ratios decreases of 40% for NAA/Cr, 20% for NAA/Cho
and 10% for NAA/Cr, while mI increased by 30% in com-
parison to healthy control (Figure 5). The second spec-
H. [arac et al.: Mri and 1H-Mr Spectroscopy in Fragile X-Premutation, Coll. Antropol. 35 (2011) Suppl. 1: 327–332
328
Fig. 1. Twenty-three-year-old woman with FXTAS. Head MR im-
age of the patient using FLAIR sequences shows global brain at-
rophy.
Fig. 2. T2-weigted MR image demonstrating high intensity sig-
nal in the basis pontis.
trum was obtained from pons and showed peak ratios de-
crease of 15% for NAA/Cr, no difference from normal
values for NAA/Cho, while mL increased by 10% (Figure
6). The third spectrum was obtained from cerebellar
white matter and showed peak ratios decrease of 40% for
NAA/Cr, while NAA/Cho, Cho/Cr and mL were normal
(Figure 7).
Given the patient’s presentation with tremor, ataxia,
cognitive impairment, autism, behavioral issues includ-
ing poor eye contact, anxiety, selective mutism, attention
problem and positive family history whereas her brother
who died young with ataxia, psychiatric problems, and
other problems suggestive of hereditary neurological dis-
ease, we suspected FXTAS and requested FMR1 gene
analysis.
Methods
Testing for abnormal expansion of the CGG repeat in
the FMR-1 gene was performed by using polymerase
chain reaction (PCR) amplification with Expand Long
enzime and Southern blot analysis of restriction endo-
nuclease digested genomic DNA from leukocytes. High
resolution techniques of the selection, such as capilary
electrophoresis of products and visualisation by using
fluorescent marked novice are performed25,26. Visualisa-
tion of reproducted sequences is performed by using the
Southern blot method of the hibridisation. This method
enable detection of the triplet expansion in the fragile X
syndrome. Detection of the hibridisation probes on the
membrane is performed by using DIG Wash and Block
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Fig. 3. T2 weighted MR images showing a less prominent signal
in the cerebellar deep white matter compared to the pons.
Fig. 4. T2 weighted images showing no atrophy of the middle
cerebellar peduncle.
Fig. 5.Magnetic resonance spectroscopy (MRS) of the left globus
pallidus demonstrating decreased NAA/Cr (40%), decreased
NAA/Cho ratio (10%) and decreased Cho/Cr ratio (10%) (in com-
parison to control).
Fig. 6. MRS of the basis pontis shows reduced NAA/Cr ratio
(15%), normal NAA/cho ratio, increased mI ratio (10%).
Buffer Set (Roche), antibody solution Anti-Digoxigenin-
-AP (Roche) and CDP-Star substrate (Roche). CGG re-
peat region of the FMR1 gene was analysed restrictive
endonuclease to digest the genomic DNA and the Dig-
-5(CGG) (Roche) probe, which contains sequences ho-
mologous to the FMR1 gene.
Results
DNA analysis revealed that our patient was a FMR1
premutation carrier with 100 CGG repeats in the abnor-
mal allele and 29 CGG repeats in the normal allele. The
accuracy of sizing was consistent between both methods,
PCR and Southern blot analysis.
Discusion
FXTAS is generally thought to affect men11–15, women
being considered to be protected against the develop-
ment of the neurologic symptoms by the second X chro-
mosome13,14. Recent reports document that isolated wo-
men carriers of the expanded FMR1 gene have FXTAS
with less severe neuropsychiatric symptoms12,13. Female
premutation carriers usually present with psychiatric
problems, such as social phobia, anxie27.
Our patient who was believed to have some metabolic
disorder due to tremor, ataxia, cognitive symptoms and
presence of high concentratrions of urine amino acids,
was diagnosed with FXTAS syndrome on the basis of
clinical symptoms, neuroimaging findings including MRI,
MRS and genetic testing.
In contrast to previous reports which described less
severe neurologic disturbances in women later in life, we
report an isolated case of early-onset FXTAS in a young
woman, who progressively developed severe neurological
disturbances. Perhaps the abnormally long CGG repeat
of 100 repeats played an important role in making neuro-
logic symptoms more manifest. Cohen et al.28 reported a
correlation between CGG repeat length and reductions
in IQ and increased ventricular volume, in patients with
premutation.
Al-Hinti et al.29 reported that abnormally long 103-
-CGG repeat correlated with patient’s symptomatic se-
verity. FXTAS arises when neuropsychiatric disturbances
are associated with abnormalities visible on MRI3,23,29.
MRI usually reveals moderate cerebral atrophy, minimal
changes in the pons and deep cerebellar white matter,
and enlargement of the fourth ventricle. Our case sho-
wed no high T2 signal and no atrophy in the MCPs.
In the absence of the characteristic high T2 signal in-
tensity in the MCP, the diagnosis of the definite FXTAS
cannot be established according to the clinical classifica-
tion criteria of Jacquemont et al.2 and Brunberg et al.23
Radiologic findings in the MCP are thought to be specific
for the FXTAS and are related to the spongiform changes
observed in the same regions23. However, characteristic
brain MRI high intensity signal in the MCP is not always
present in women or may be unremarkable12. Nonethe-
less, the less prominent abnormalities in the deep white
matter of the cerebellum and pons in the absence of the
bilateral signal changes in the MCPs in our patient is
fully correlated with findings reported from Al-Hinti et
al. in one woman with fragile X premutation with cogni-
tive impairment, tremor, and history of premature ovar-
ian failure26. Recently Adams et al.29 have found, using
volumetric brain changes in women with FXTAS, less
pronounced reductions of cerebellar volume and lower
incidence of involvement (symmetric high T2 signal) of
the MCP (13%) affected by FXTAS compared to affected
men (58%). These authors also observed significant cor-
relation between increased length of CGG repeat, sever-
ity of FXTAS symptoms, and reduced cerebellar volume.
However, prediction of the severity of the symptoms of
fragile X syndrome is limited30.
Ginestroni et al.31 found decreased pontine NAA/Cr
ratio in one of three patient with FXTAS by using 1H-MR
spectroscopy of the brainstem and cerebellum. In our pa-
tient the spectra was the most suggestive of multiple sys-
tem atrophy32,33. Recent 1H-MRS studies of the striatum
revealed reduced NAA/Cr ratio in MSA patients and the
preserved NAA/Cr ratio in Parkinson’s disease (PD) pa-
tients. The reduced NAA/Cr ratio probably reflects stria-
tal neuronal loss32. Watanabe et al. reported that the
NAA/Cr in MSA patient shows a significant reduction in
the putamen and the pontine base, as well as in the cere-
bral white matter in long duration cases, even from the
early phase of the disease, in patients who show no ataxic
symptoms or parkinsonism, or in those with unremark-
able MRI findings33. Furthemore, our patient is an exam-
ple of a more difficult case because additional spectro-
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Fig. 7. Metabolite ratio of the cerebellar deep white matter re-
vealed decreased NAA/cr ratio (40%), and normal NAA/Cho and
Cho/Cr ratio.
scopic metabolite abnormalities were detected. Slightly
reduced NAA/Cr ratio (15%) was detected in the pons,
but the same parameter was very much decreased in the
globus pallidus (40%) and cerebellar white matter (40%).
Becasue NAA is considered a neuronal marker, our re-
sults of decreased NAA/Cr in the globus pallidus, cerebel-
lar white matter, and pons suggest loss of neuronal via-
bility in the course of significant degeneration in these
regions. Also, we found moderately increased mI/Cr ratio
in the globus pallidus (30%) and slightly elevated pontine
ml (a glial marker) level. We found no excess of Cho/Cr
ratio suggesting that neither axonal degeneration nor
demyelination of subcortical white matter occurred. Gi-
nestroni et al. also reported decreased level of NAA in the
pons only in one of three patients30.
Although FXTAS syndrome has already been docu-
mented in women12–14, no in vivo MRS studies for the de-
tection and quantification of neurodegenerative changes
in FXTAS have been performed in such a young female
patient. Despite lacking pathologic confirmation, clinical
diagnosis of FXTAS was firmly established by using the
diagnostic criteria2,4,12, including MRI, and by additional
investigations such as neuropsychology examination, EEG,
cognitive evoked potentials and 1H-MR spectroscopy. The
final diagnosis is established by using genetic testing. Al-
though neuropsychological investigation showed signifi-
cant functional impairment of frontal, parietal, and tem-
poral lobes, and of subcortical structures, such as basal
ganglia, these findings only suggest the diagnosis of
FXTAS, but do not provide an explanation of mecha-
nisms by which the brain is affected in FXTAS. Our re-
port provides unusual case of young woman, carrier of
the fragile X premutation, who exhibited severe neuro-
logical disturbances. Practitioners should be aware of
FXTAS in any woman presenting with a triad of ataxia,
tremor, and cognitive impairment, particularly if positive
family history exists. Atrophy and spectroscopic meta-
bolic changes in FXTAS are entirely consistent with the
pathologic pattern of MSA patients32, but differ to some
extent from those of olivopontocerebellar atrophy (OPCA)
and dementia33.
Conclusion
Carriers of premutation alleles (55–200 CGG repeats)
of FMR1 are now being identified with one or more clini-
cal syndromes, including mild cognitive dysfunction, be-
havioral deficits, and a neurodegenerative disorder not
only among older adult but also in young carriers. Awa-
reness of these syndromes is important for clinicians, es-
pecially neurologists and psychiatrists when they en-
counter patients with tremor, ataxia, parkinsonism, and
cognitive dysfunction. The clinical assessment in such
patients requires obtaining clinical examination, specific
neuroimaging studies, including brain imaging and mo-
lecular genetic diagnostic tools. Metabolic screening tests
such as quantitative studies for amino acids in blood and
urine, plasma lactate, ammonia, urine analysis for amino
acids should also be considered upon consultation with a
geneticist. Individuals for whom fragile X syndrome test-
ing should be considered include mental retardation of
unknown etiology, autism or autism spectrum disorder-
-not otherwisw specified or Asperger syndrome, women
with premature ovarian dysfunction 40 years of age of
unknown etilogy, learning disability, behavioral issues in-
cluding poor eye contact, anxiety, selective mutism, at-
tention problems, hyperactivity, men and women who ex-
perience primarily late-onset or early-onset intention
tremor and cerebellar ataxia of unknown origin, espe-
cially if they have a positive family history of movement
disorders or fragile X syndrome and developmental delay.
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FRAGILNI X-VEZANI TREMOR/ATAXIA SINDROM (FXTAS) U MLADE @ENE: KLINI^KA,
GENETSKA, MRI I 1H-MR SPEKTROSKOPSKA KORELACIJA
S A @ E T A K
Poznato je da X-vezani tremor/ataxia sindrom (FXTAS) predstavlja neurodegenerativnu bolest s kasnim nastupom
prvenstveno kod mu{kih mosilaca premutacije (55–200 CGG ponavljanja) na FMR 1 genu (fragile X mentalna retarda-
cija). Ipak postoji nekolik opoisanih slu~ajeva oboljelih `ena sa FXTAS. Opisujemo 23-godi{nju djevojku sa pozitivnom
obiteljskom anamnezom mentalne retardacije i autizma sa simptomima tremora, ataksije, emocionalne nestabilnosti i
kognitivnih disfunkcija. Magnetska rezonancija (MRI) mozga otkrila je difuznu kortikalnu atrofiju, dok je spektro-
skopija magnetskom rezonancijom (MRS) pokazala sni`enu razinu N-acetilaspartata (NAA) u cerebelumu, bazalnim
ganglijima i ponsu u odnosu na nalaze zdravih pojedinaca. Genetsko testiranje potvrdilo je heterozigotnu premutaciju
FMR 1 gena sa 100 ponavljanja u abnormalnom alelu i 29 CGG ponavljanja u normalnom alelu. Zaklju~ujemo, da bi
FXTAS mogla biti nedovoljno prepoznata bolest, posebno u `ena.
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